John Kollins is the founder of Satsuma Pharmaceuticals. Satsuma Pharmaceuticals has raised $74M in total funding. Latest round: Series A.
John Kollins is the President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company he co-founded to develop STS101 for the acute treatment of migraines. He has more than 30 years of biopharmaceutical industry experience.
Full founder directory · Investor directory · Company funding database · Fundraising library